Details
Stereochemistry | ACHIRAL |
Molecular Formula | C29H26ClFN4O4S |
Molecular Weight | 581.058 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC=C3N=CN=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)C3=C2
InChI
InChIKey=BCFGMOOMADDAQU-UHFFFAOYSA-N
InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
DescriptionCurator's Comment: Description was created based on several sources, including
http://adisinsight.springer.com/drugs/800015425
Curator's Comment: Description was created based on several sources, including
http://adisinsight.springer.com/drugs/800015425
Lapatinib is a small molecule and a member of the 4-anilinoquinazoline class of kinase inhibitors. It is present as the monohydrate of the ditosylate salt (trade name TYKERB). Lapatinib is dual inhibitor of the EGFR (epidermal growth factor receptor; also called HER1 or ErbB1) and HER2 receptor tyrosine kinases. Lapatinib was developed by GlaxoSmithKline, however, Novartis subsequently acquired all the rights to the drug from GlaxoSmithKline. TYKERB is indicated in combination therapy for the treatment of metastatic breast cancer that overexpresses the HER2 receptor.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25977884
Curator's Comment: Increased lapatinib uptake was observed in brain metastases but not in normal brain.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL203 |
3.0 nM [Ki] | ||
Target ID: CHEMBL1824 |
13.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TYKERB Approved UseTYKERB® is indicated in combination with: •capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitation of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine. •letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. TYKERB, a kinase inhibitor, is indicated in combination with: (1) •capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitation of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine. •letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. Launch Date1.17374399E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.43 μg/mL |
1250 mg 1 times / day steady-state, oral dose: 1250 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LAPATINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
36.2 μg × h/mL |
1250 mg 1 times / day steady-state, oral dose: 1250 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LAPATINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
24 h |
1250 mg 1 times / day steady-state, oral dose: 1250 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LAPATINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
LAPATINIB plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1250 mg 1 times / day steady, oral MTD Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: whole brain radiotherapy Sources: |
unhealthy, 50 years (range: 30–78 years) n = 27 Health Status: unhealthy Condition: (HER2)-positive breast cancer Age Group: 50 years (range: 30–78 years) Sex: F Population Size: 27 Sources: |
DLT: Rash, Diarrhea... Dose limiting toxicities: Rash (grade 3, 2 patients) Sources: Diarrhea (grade 3, 2 patients) Hypoxia (grade 3, 1 patient) Pulmonary embolus (grade 4, 2 patients) |
1500 mg 1 times / day steady, oral Dose: 1500 mg, 1 times / day Route: oral Route: steady Dose: 1500 mg, 1 times / day Co-administed with:: whole brain radiotherapy Sources: |
unhealthy, 50 years (range: 30–78 years) n = 5 Health Status: unhealthy Condition: (HER2)-positive breast cancer Age Group: 50 years (range: 30–78 years) Sex: F Population Size: 5 Sources: |
DLT: Mucositis, Rash... Dose limiting toxicities: Mucositis (grade 3, 2 patients) Sources: Rash (grade 3, 2 patients) |
1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Disc. AE: Diarrhea... Other AEs: Diarrhea, Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (grade 4, 1%) Other AEs:Diarrhea (all grades, 65%) Sources: Diarrhea (grade 3, 13%) Nausea (all grades, 44%) Nausea (grade 3, 2%) Vomiting (all grades, 26%) Vomiting (grade 3, 2%) Stomatitis (all grades, 14%) Dyspepsia (all grades, 11%) Dyspepsia (grade 3, <1%) Palmar-plantar erythrodysesthesia syndrome (all grades, 53%) Palmar-plantar erythrodysesthesia syndrome (grade 3, 12%) Rash (all grades, 28%) Rash (grade 3, 2%) Dermatitis acneiform (grade 3, <1%) Dry skin (all grades, 10%) Mucosal inflammation (all grades, 15%) Pain in extremity (all grades, 12%) Pain in extremity (grade 3, 1%) Back pain (all grades, 11%) Back pain (grade 3, 1%) Dyspnea (all grades, 12%) Dyspnea (grade 3, 3%) Insomnia (all grades, 10%) Insomnia (grade 3, <1%) Hepatotoxicity (severe|grade 5) Bilirubin total increased (grade 3, 4%) Bilirubin total increased (grade 1-2, 41%) AST increased (grade 3, 2%) AST increased (grade 4, <1%) AST increased (grade 1-2, 46%) ALT increased (grade 3, 2%) ALT increased (grade 1-2, 35%) |
1800 mg 1 times / day steady, oral MTD Dose: 1800 mg, 1 times / day Route: oral Route: steady Dose: 1800 mg, 1 times / day Sources: |
unhealthy, 60 years (range: 37 – 73 years) n = 6 Health Status: unhealthy Condition: Solid Tumors Age Group: 60 years (range: 37 – 73 years) Sex: M+F Population Size: 6 Sources: |
DLT: Diarrhea, Gamma GT increased... Other AEs: Stomatitis, Rash... Dose limiting toxicities: Diarrhea (grade 3, 2 patients) Other AEs:Gamma GT increased (grade 3, 1 patient) Stomatitis (grade 1, 1 patient) Sources: Rash (grade 2, 2 patients) Seborrheic dermatitis (grade 1, 1 patient) Paronychia (grade 1, 1 patient) Anorexia (grade 1, 3 patients) Lymphocyte count decreased (grade 1, 1 patient) |
1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: Letrozole(2.5 mg/day) Sources: |
unhealthy, 63 years n = 111 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 63 years Sex: F Population Size: 111 Sources: |
Other AEs: Hepatotoxicity, Bilirubin total increased... Other AEs: Hepatotoxicity (severe|grade 5) Sources: Bilirubin total increased (grade 3, <1%) Bilirubin total increased (grade 4, <1%) Bilirubin total increased (grade 1-2, 20%) AST increased (grade 3, 6%) AST increased (grade 1-2, 47%) ALT increased (grade 3, 5%) ALT increased (grade 4, <1%) ALT increased (grade 1-2, 40%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypoxia | grade 3, 1 patient DLT |
1250 mg 1 times / day steady, oral MTD Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: whole brain radiotherapy Sources: |
unhealthy, 50 years (range: 30–78 years) n = 27 Health Status: unhealthy Condition: (HER2)-positive breast cancer Age Group: 50 years (range: 30–78 years) Sex: F Population Size: 27 Sources: |
Diarrhea | grade 3, 2 patients DLT |
1250 mg 1 times / day steady, oral MTD Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: whole brain radiotherapy Sources: |
unhealthy, 50 years (range: 30–78 years) n = 27 Health Status: unhealthy Condition: (HER2)-positive breast cancer Age Group: 50 years (range: 30–78 years) Sex: F Population Size: 27 Sources: |
Rash | grade 3, 2 patients DLT |
1250 mg 1 times / day steady, oral MTD Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: whole brain radiotherapy Sources: |
unhealthy, 50 years (range: 30–78 years) n = 27 Health Status: unhealthy Condition: (HER2)-positive breast cancer Age Group: 50 years (range: 30–78 years) Sex: F Population Size: 27 Sources: |
Pulmonary embolus | grade 4, 2 patients DLT |
1250 mg 1 times / day steady, oral MTD Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: whole brain radiotherapy Sources: |
unhealthy, 50 years (range: 30–78 years) n = 27 Health Status: unhealthy Condition: (HER2)-positive breast cancer Age Group: 50 years (range: 30–78 years) Sex: F Population Size: 27 Sources: |
Mucositis | grade 3, 2 patients DLT |
1500 mg 1 times / day steady, oral Dose: 1500 mg, 1 times / day Route: oral Route: steady Dose: 1500 mg, 1 times / day Co-administed with:: whole brain radiotherapy Sources: |
unhealthy, 50 years (range: 30–78 years) n = 5 Health Status: unhealthy Condition: (HER2)-positive breast cancer Age Group: 50 years (range: 30–78 years) Sex: F Population Size: 5 Sources: |
Rash | grade 3, 2 patients DLT |
1500 mg 1 times / day steady, oral Dose: 1500 mg, 1 times / day Route: oral Route: steady Dose: 1500 mg, 1 times / day Co-administed with:: whole brain radiotherapy Sources: |
unhealthy, 50 years (range: 30–78 years) n = 5 Health Status: unhealthy Condition: (HER2)-positive breast cancer Age Group: 50 years (range: 30–78 years) Sex: F Population Size: 5 Sources: |
Dry skin | all grades, 10% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Insomnia | all grades, 10% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Back pain | all grades, 11% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Dyspepsia | all grades, 11% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Dyspnea | all grades, 12% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Pain in extremity | all grades, 12% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Stomatitis | all grades, 14% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Mucosal inflammation | all grades, 15% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Vomiting | all grades, 26% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Rash | all grades, 28% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Nausea | all grades, 44% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Palmar-plantar erythrodysesthesia syndrome | all grades, 53% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Diarrhea | all grades, 65% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
ALT increased | grade 1-2, 35% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Bilirubin total increased | grade 1-2, 41% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
AST increased | grade 1-2, 46% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Back pain | grade 3, 1% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Pain in extremity | grade 3, 1% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Palmar-plantar erythrodysesthesia syndrome | grade 3, 12% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Diarrhea | grade 3, 13% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
ALT increased | grade 3, 2% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
AST increased | grade 3, 2% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Nausea | grade 3, 2% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Rash | grade 3, 2% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Vomiting | grade 3, 2% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Dyspnea | grade 3, 3% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Bilirubin total increased | grade 3, 4% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Dermatitis acneiform | grade 3, <1% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Dyspepsia | grade 3, <1% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Insomnia | grade 3, <1% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Diarrhea | grade 4, 1% Disc. AE |
1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
AST increased | grade 4, <1% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Hepatotoxicity | severe|grade 5 | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: capecitabine(2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle) Sources: |
unhealthy, 53 years n = 198 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 53 years Sex: F Population Size: 198 Sources: |
Lymphocyte count decreased | grade 1, 1 patient | 1800 mg 1 times / day steady, oral MTD Dose: 1800 mg, 1 times / day Route: oral Route: steady Dose: 1800 mg, 1 times / day Sources: |
unhealthy, 60 years (range: 37 – 73 years) n = 6 Health Status: unhealthy Condition: Solid Tumors Age Group: 60 years (range: 37 – 73 years) Sex: M+F Population Size: 6 Sources: |
Paronychia | grade 1, 1 patient | 1800 mg 1 times / day steady, oral MTD Dose: 1800 mg, 1 times / day Route: oral Route: steady Dose: 1800 mg, 1 times / day Sources: |
unhealthy, 60 years (range: 37 – 73 years) n = 6 Health Status: unhealthy Condition: Solid Tumors Age Group: 60 years (range: 37 – 73 years) Sex: M+F Population Size: 6 Sources: |
Seborrheic dermatitis | grade 1, 1 patient | 1800 mg 1 times / day steady, oral MTD Dose: 1800 mg, 1 times / day Route: oral Route: steady Dose: 1800 mg, 1 times / day Sources: |
unhealthy, 60 years (range: 37 – 73 years) n = 6 Health Status: unhealthy Condition: Solid Tumors Age Group: 60 years (range: 37 – 73 years) Sex: M+F Population Size: 6 Sources: |
Stomatitis | grade 1, 1 patient | 1800 mg 1 times / day steady, oral MTD Dose: 1800 mg, 1 times / day Route: oral Route: steady Dose: 1800 mg, 1 times / day Sources: |
unhealthy, 60 years (range: 37 – 73 years) n = 6 Health Status: unhealthy Condition: Solid Tumors Age Group: 60 years (range: 37 – 73 years) Sex: M+F Population Size: 6 Sources: |
Anorexia | grade 1, 3 patients | 1800 mg 1 times / day steady, oral MTD Dose: 1800 mg, 1 times / day Route: oral Route: steady Dose: 1800 mg, 1 times / day Sources: |
unhealthy, 60 years (range: 37 – 73 years) n = 6 Health Status: unhealthy Condition: Solid Tumors Age Group: 60 years (range: 37 – 73 years) Sex: M+F Population Size: 6 Sources: |
Rash | grade 2, 2 patients | 1800 mg 1 times / day steady, oral MTD Dose: 1800 mg, 1 times / day Route: oral Route: steady Dose: 1800 mg, 1 times / day Sources: |
unhealthy, 60 years (range: 37 – 73 years) n = 6 Health Status: unhealthy Condition: Solid Tumors Age Group: 60 years (range: 37 – 73 years) Sex: M+F Population Size: 6 Sources: |
Gamma GT increased | grade 3, 1 patient DLT |
1800 mg 1 times / day steady, oral MTD Dose: 1800 mg, 1 times / day Route: oral Route: steady Dose: 1800 mg, 1 times / day Sources: |
unhealthy, 60 years (range: 37 – 73 years) n = 6 Health Status: unhealthy Condition: Solid Tumors Age Group: 60 years (range: 37 – 73 years) Sex: M+F Population Size: 6 Sources: |
Diarrhea | grade 3, 2 patients DLT, Disc. AE |
1800 mg 1 times / day steady, oral MTD Dose: 1800 mg, 1 times / day Route: oral Route: steady Dose: 1800 mg, 1 times / day Sources: |
unhealthy, 60 years (range: 37 – 73 years) n = 6 Health Status: unhealthy Condition: Solid Tumors Age Group: 60 years (range: 37 – 73 years) Sex: M+F Population Size: 6 Sources: |
Bilirubin total increased | grade 1-2, 20% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: Letrozole(2.5 mg/day) Sources: |
unhealthy, 63 years n = 111 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 63 years Sex: F Population Size: 111 Sources: |
ALT increased | grade 1-2, 40% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: Letrozole(2.5 mg/day) Sources: |
unhealthy, 63 years n = 111 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 63 years Sex: F Population Size: 111 Sources: |
AST increased | grade 1-2, 47% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: Letrozole(2.5 mg/day) Sources: |
unhealthy, 63 years n = 111 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 63 years Sex: F Population Size: 111 Sources: |
ALT increased | grade 3, 5% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: Letrozole(2.5 mg/day) Sources: |
unhealthy, 63 years n = 111 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 63 years Sex: F Population Size: 111 Sources: |
AST increased | grade 3, 6% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: Letrozole(2.5 mg/day) Sources: |
unhealthy, 63 years n = 111 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 63 years Sex: F Population Size: 111 Sources: |
Bilirubin total increased | grade 3, <1% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: Letrozole(2.5 mg/day) Sources: |
unhealthy, 63 years n = 111 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 63 years Sex: F Population Size: 111 Sources: |
ALT increased | grade 4, <1% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: Letrozole(2.5 mg/day) Sources: |
unhealthy, 63 years n = 111 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 63 years Sex: F Population Size: 111 Sources: |
Bilirubin total increased | grade 4, <1% | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: Letrozole(2.5 mg/day) Sources: |
unhealthy, 63 years n = 111 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 63 years Sex: F Population Size: 111 Sources: |
Hepatotoxicity | severe|grade 5 | 1250 mg 1 times / day steady, oral Recommended Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Co-administed with:: Letrozole(2.5 mg/day) Sources: |
unhealthy, 63 years n = 111 Health Status: unhealthy Condition: stage IV breast cancer | estrogen receptor+ |progesterone receptor+ Age Group: 63 years Sex: F Population Size: 111 Sources: |
Overview
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. | 2001 Dec |
|
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. | 2003 Aug |
|
Gateways to clinical trials. | 2003 Oct |
|
Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. | 2004 Feb 1 |
|
Early success of combined EGFR and Her2 receptor blockade as a clinical strategy in breast cancer. | 2004 Jun |
|
Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. | 2005 |
|
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. | 2005 Apr 10 |
|
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. | 2005 Aug 10 |
|
GlaxoSmithKline cancer drug threatens Herceptin market. | 2005 Dec |
|
Role of tyrosine kinase inhibitors in cancer therapy. | 2005 Dec |
|
The epidermal growth factor receptor as a target for colorectal cancer therapy. | 2005 Feb |
|
Gateways to clinical trials. | 2005 Jan-Feb |
|
Gateways to clinical trials. | 2005 Jun |
|
Gateways to clinical trials. | 2005 Mar |
|
EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head. | 2005 Mar |
|
Antitumor activity of HER-2 inhibitors. | 2005 Sep 8 |
|
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. | 2006 Dec 28 |
|
Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. | 2006 Feb |
|
Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). | 2006 Feb 2 |
|
Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. | 2006 Jul |
|
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. | 2006 Jul 15 |
|
[Molecular diagnostic and targeted therapy--"Barking dogs are going to bite": presentations from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta 2006]. | 2006 Oct |
|
Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. | 2006 Oct 16 |
|
Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? | 2006 Sep 18 |
|
Three new drugs available to fight kidney cancer. | 2006 Sep 6 |
|
HER-2-positive breast cancer: hope beyond trastuzumab. | 2007 |
|
Lapatinib plus capecitabine in breast cancer. | 2007 Apr 5 |
|
The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. | 2007 Feb |
|
Gateways to clinical trials. | 2007 Jan-Feb |
|
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. | 2007 Jun |
|
The EGF receptor Hokey-Cokey. | 2007 Mar |
Patents
Sample Use Guides
The recommended dosage of TYKERB for advanced or metastatic breast cancer is 1,250 mg (5 tablets) given orally once daily on Days 1-21 continuously in combination with capecitabine 2,000 mg/m2 /day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle. The recommended dose of TYKERB for hormone receptor positive, HER2 positive metastatic breast cancer is 1500 mg (6 tablets) given orally once daily continuously in combination with letrozole. When TYKERB is coadministered with letrozole, the recommended dose of letrozole is 2.5 mg once daily. • TYKERB should be taken at least one hour before or one hour after a meal. However, capecitabine should be taken with food or within 30 minutes after food. • TYKERB should be taken once daily. Do not divide daily doses of TYKERB. • Modify dose for cardiac and other toxicities, severe hepatic impairment, and CYP3A4 drug interactions.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22964224
lapatinib-induced time- and dose-dependent phosphorylation dynamics in SKBR3 breast cancer cells. Among 4953 identified phosphopeptides from 1548 proteins, a small proportion (5-7%) was regulated at least twofold by 1-10 μm lapatinib.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175605
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
||
|
NDF-RT |
N0000175076
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
||
|
WHO-VATC |
QL01XE07
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
||
|
NCI_THESAURUS |
C155764
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
||
|
LIVERTOX |
NBK547971
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
||
|
NCI_THESAURUS |
C2167
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
||
|
FDA ORPHAN DRUG |
284209
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
||
|
WHO-ATC |
L01XE07
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL554
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
480167
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | RxNorm | ||
|
Lapatinib
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
1548
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
C490728
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
727989
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
208908
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
C26653
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
0VUA21238F
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
SUB25379
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
5692
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
8209
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
DTXSID7046675
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
M6688
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | Merck Index | ||
|
8378
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
LAPATINIB
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
231277-92-2
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
DB01259
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY | |||
|
0VUA21238F
Created by
admin on Fri Dec 16 20:04:50 UTC 2022 , Edited by admin on Fri Dec 16 20:04:50 UTC 2022
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE TOXIC (PARENT)
SALT/SOLVATE (PARENT)